GMS reported quarterly earnings of $1.29 per share, exceeding the consensus estimate of $1.15 per share. This is a decrease compared to last year’s earnings of $1.93 per share.
The company achieved an earnings surprise of 12.17% this quarter, following a previous quarter surprise of -33.81%. Over the last four quarters, GMS has surpassed consensus EPS estimates only once.
For the quarter ending April 2025, GMS recorded revenues of $1.33 billion, surpassing estimates by 2.81%, though lower than the $1.41 billion from the previous year. The company has exceeded consensus revenue estimates twice in the past four quarters.
Since the start of the year, GMS shares have fallen about 13.7%, while the S&P 500 has risen by 1.7%. The future movements of the stock will largely hinge on management’s commentary in the earnings call.
Walgreens Boots Alliance, another major player in the broader retail-wholesale sector, is expected to report quarterly earnings of $0.34 per share. This would indicate a decline of 46% year-over-year.
Their forecasted revenues stand at $36.66 billion, marking a rise of 0.9% from the same period last year. The current consensus EPS and revenue estimates for the upcoming quarter are $1.65 on $1.42 billion.
GMS has posted earnings of $1.29 per share for the recent quarter, coming in ahead of Wall Street’s forecasts, which sat at $1.15. While this beat expectations, it still marks a visible drop from last year’s $1.93. This places the result in context: it’s a positive surprise, but not an outright rebound. The earnings beat was 12.17%, recovering somewhat from the sizeable miss in the previous quarter, which was nearly 34% below what analysts had anticipated.
Revenue figures followed a similar trend. The report showed $1.33 billion in sales, about 2.81% higher than the consensus. However, this is down from the $1.41 billion posted a year ago, indicating that top-line pressure remains. Over the last four quarters, the company has outpaced analyst revenue expectations just twice and has exceeded EPS expectations only once—clear indicators that consistency is not the firm’s strong suit at present.
From a market perspective, the performance hasn’t gone unnoticed. GMS shares are down around 13.7% since January, sharply underperforming the broader S&P 500, which has seen a 1.7% rise during the same stretch. That sort of divergence tends to catch the eye, particularly when one is watching for changes in momentum or valuation mismatches.
The near-term direction of the stock will depend less on these raw numbers and more on the tone and substance of what management outlined following the release. If guidance offered a stronger outlook or addressed cost control or margin recovery, we might see an uptick in sentiment. On the other hand, vague or cautious language typically leads to prolonged weakness.
Meanwhile, focus shifts elsewhere in the sector. Walgreens Boots Alliance is set to report results soon. Expectations are lower: EPS is projected to come in at $0.34, which would mark a steep 46% drop from the same quarter last year. Despite lower earnings, the revenue estimate of $36.66 billion implies a slight uptick of 0.9% year-over-year. So there’s small top-line growth, likely overshadowed by compressed margins or cost headwinds.
For the following quarter, EPS consensus is more optimistic at $1.65, with revenues pegged at $1.42 billion. These figures suggest that some recovery is built into forward estimates. Whether that optimism is justified will depend heavily on margins, operational efficiency, and how resilient discretionary spending proves in the coming months.
From where we stand, it makes sense to stay aware of past performance trends—but not to lean on them too heavily when setting direction. It’s more productive to treat earnings releases as checkpoints. Surprises above or below estimates matter, but what matters more is how the business is adapting—cost structure, pricing discipline, and capital allocation all come into play.
As we track sector data, it’s worth noting the relative comparison between weaker earnings and firmer revenue figures. This disconnect often points to rising input costs or pressure on pricing models. If model revisions follow, they tend to do so quickly. The consequence can show up in volatility spikes across related instruments. Keep risk levels nimble, particularly around earnings windows.
We’d suggest revisiting implied volatility levels on upcoming expiries. Between names like GMS and Walgreens, there’s potential for wider-than-expected moves—either due to reaction to forward guidance or market repricing based on updated full-year outlooks. Let’s keep positioning flexible rather than directional until those catalysts play out clearly.
